LivaNova launches post-market study of bioprosthetic aortic heart valves

LivaNova (NSDQ:LIVN) announced today that the first patient has been enrolled in a post-market trial evaluating the overall incidence of reduced leaflet motion identified by CT imaging in patients receiving a bioprosthetic aortic heart valve. Four-dimensional CT scans will be taken of the trial’s 230 participants at least 30 days after they stop anticoagulation or dual antiplatelet therapy, according to LivaNova. The study will also include one year of follow-up. “Thrombus formation on valve leaflets has been shown to occur in some patients receiving prosthetic tissue valve replacement via transcatheter or open surgical procedures and may lead to leaflet thickening and immobility,” Brian Duncan, LivaNova’s VP of medical affairs in cardiac surgery, said in prepared remarks. “Believe is the first trial to examine this process with advanced imaging and a standardized approach to anticoagulation in patients undergoing implantation of LivaNova bioprosthetic aortic valves.” “The Believe study is designed to enhance the understanding of reduced leaflet motion phenomenon, while providing important information to clinicians and patients to ensure the best possible outcomes after surgical aortic valve replacement,” Dr. Basel Ramlawi, who enrolled the first patient in the trial and is the attending cardiothoracic surgeon and chairman of The Heart & Vascular Center at Valley Health System, added. London-based LivaNova also said today that ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiovascular Clinical Trials Imaging Wall Street Beat LivaNova Source Type: news